RT Journal Article
T1 Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
A1 Ortiz Ruiz, Alejandra
A1 Ruiz Heredia, Yanira
A1 Morales, María Luz
A1 Aguilar Garrido, Pedro
A1 García Ortiz, Almudena
A1 Valeri Lozano, Antonio
A1 Bárcena Asensio, María Carmen
A1 García Martín, Rosa María
A1 Garrido, Vanesa
A1 Moreno Gutiérrez, Laura
A1 Gimenez, Alicia
A1 Navarro Aguadero, Miguel Ángel
A1 Velasco Estévez, María
A1 Lospitao, Eva
A1 Cedena Romero, M. Teresa
A1 Barrio, Santiago
A1 Martínez López, Joaquín
A1 Linares Gómez, María
A1 Gallardo, Miguel
AB Mitochondria are involved in the development and acquisition of a malignant phenotype in hematological cancers. Recently, their role in the pathogenesis of multiple myeloma (MM) has been suggested to be therapeutically explored. MYC is a master regulator of b-cell malignancies such as multiple myeloma, and its activation is known to deregulate mitochondrial function. We investigated the impact of mitochondrial activity on the distinct entities of the disease and tested the efficacy of the mitochondrial inhibitor, tigecycline, to overcome MM proliferation. COXII expression, COX activity, mitochondrial mass, and mitochondrial membrane potential demonstrated a progressive increase of mitochondrial features as the disease progresses. In vitro and in vivo therapeutic targeting using the mitochondrial inhibitor tigecycline showed promising efficacy and cytotoxicity in monotherapy and combination with the MM frontline treatment bortezomib. Overall, our findings demonstrate how mitochondrial activity emerges in MM transformation and disease progression and the efficacy of therapies targeting these novel vulnerabilities.
PB MPDI
SN 2072-6694
YR 2021
FD 2021-04-01
LK https://hdl.handle.net/20.500.14352/6886
UL https://hdl.handle.net/20.500.14352/6886
LA eng
NO Ortiz-Ruiz A, Ruiz-Heredia Y, Morales ML, Aguilar-Garrido P, García-Ortiz A, Valeri A, et al. Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma. Cancers 2021;13:1662. https://doi.org/10.3390/cancers13071662.
NO This work was funded by project PI 18/00295, PI18/01519 and CP19/00140 from the Insti- tuto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) and cofunded by the Eu- ropean Regional Development Fund, CRIS contra el Cancer Foundation, AECC (INVES19015GALL) and Madri+d from Comunidad de Madrid YEI (PEJD-2017-PRE/BMD-4835 and PEJD-2019-POST/ BMD-14505) and approved by the Ethics Committee of our Institution.
NO Instituto de Salud Carlos III
NO Asociación Española Contra el Cáncer: Fundación CRIS contra el cáncer
NO Comunidad de Madrid
NO Ministerio de Economía, Comercio y Empresa (España)
NO Fondo Europeo de Desarrollo Regional
DS Docta Complutense
RD 17 abr 2025